Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections.
Gram-negative uropathogenic Escherichia coli (UPEC) bacteria are a causative pathogen of urinary tract infections (UTIs). Previously developed antivirulence inhibitors of the type 1 pilus adhesin, FimH, demonstrated oral activity in animal models of UTI but were found to have limited compound exposure due to the metabolic instability of the O-glycosidic bond (O-mannosides). Herein, we disclose that compounds having the O-glycosidic bond replaced with carbon linkages had improved stability and inhibitory activity against FimH. We report on the design, synthesis, and in vivo evaluation of this promising new class of carbon-linked C-mannosides that show improved pharmacokinetic (PK) properties relative to O-mannosides. Interestingly, we found that FimH binding is stereospecifically modulated by hydroxyl substitution on the methylene linker, where the R-hydroxy isomer has a 60-fold increase in potency. This new class of C-mannoside antagonists have significantly increased compound exposure and, as a result, enhanced efficacy in mouse models of acute and chronic UTI.
Fimbrion Therapeutics, Inc. , Saint Louis, Missouri 63108 United States.
Laurel
L
Mydock-McGrane
Fimbrion Therapeutics, Inc. , Saint Louis, Missouri 63108 United States.
Zachary
Z
Cusumano
Zhenfu
Z
Han
Jana
J
Binkley
Maria
M
Kostakioti
Fimbrion Therapeutics, Inc. , Saint Louis, Missouri 63108 United States.
Thomas
T
Hannan
Jerome S
JS
Pinkner
Roger
R
Klein
Vasilios
V
Kalas
Jan
J
Crowley
Department of Chemistry and Biochemistry, University of Missouri , Saint Louis, Missouri 63121 United States.
Nigam P
NP
Rath
Fimbrion Therapeutics, Inc. , Saint Louis, Missouri 63108 United States.
Scott J
SJ
Hultgren
Fimbrion Therapeutics, Inc. , Saint Louis, Missouri 63108 United States.
James W
JW
Janetka
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000187:drug effects* / Q000472:pathogenicity*; D005260:Female; D008362:Mannosides / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D008809:Mice, Inbred C3H; D008826:Microbial Sensitivity Tests; D008958:Models, Molecular; D015394:Molecular Structure; D013329:Structure-Activity Relationship; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology*; D014774:Virulence / Q000187:drug effects
D000900:Anti-Bacterial Agents; D008362:Mannosides
Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130430
24821916
Chemistry. 2011 May 27;17(23):6545-62
21523837
J Med Chem. 2012 May 24;55(10):4700-13
22519985
J Urol. 2011 Dec;186(6):2359-64
22019034
Nat Rev Microbiol. 2003 Oct;1(1):65-70
15040181
Curr Opin Cell Biol. 2003 Oct;15(5):633-9
14519399
Curr Opin Pharmacol. 2003 Oct;3(5):513-9
14559097
Mol Microbiol. 2005 Jan;55(2):441-55
15659162
ChemMedChem. 2012 Aug;7(8):1404-22
22644941
Biochem Biophys Res Commun. 1982 Apr 29;105(4):1426-32
6125146
Expert Rev Anti Infect Ther. 2012 Dec;10(12):1457-68
23253323
Ther Adv Urol. 2011 Feb;3(1):19-33
21789096
Nat Rev Drug Discov. 2010 Feb;9(2):117-28
20081869
J Med Chem. 2015 Mar 12;58(5):2221-39
25666045
Antimicrob Agents Chemother. 2006 Jun;50(6):2251-4
16723598
Infect Immun. 1984 Mar;43(3):1088-90
6142000
Infect Immun. 1987 Feb;55(2):472-6
3542836
Clin Infect Dis. 1996 Jan;22(1):91-9
8824972
IUCrJ. 2016 Feb 26;3(Pt 3):163-7
27158502
J Med Chem. 2010 Dec 23;53(24):8627-41
21105658
Bioorg Med Chem. 2011 Nov 1;19(21):6454-73
21962988
Chembiochem. 2015 May 26;16(8):1235-46
25940742
Trends Biotechnol. 2016 Jun;34(6):483-95
26875976
World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):213-27
25133024
J Am Chem Soc. 2013 Feb 20;135(7):2518-29
23360500
J Med Chem. 2013 Jul 11;56(13):5395-406
23795713
Discov Med. 2009 Dec;8(43):247-52
20040279
Int J Antimicrob Agents. 2001 Apr;17(4):343-8
11295419
Mol Microbiol. 2001 Mar;39(5):1272-84
11251843
Org Biomol Chem. 2015 Feb 21;13(7):2100-7
25525831
Antimicrob Agents Chemother. 2010 May;54(5):1855-63
20231390
PLoS Med. 2007 Dec;4(12):e329
18092884
Nat Protoc. 2009;4(8):1230-43
19644462
J Med Chem. 2012 Apr 26;55(8):3945-59
22449031
Sci Transl Med. 2011 Nov 16;3(109):109ra115
22089451
ACS Chem Biol. 2014 Jun 20;9(6):1377-85
24749535
J Pharm Bioallied Sci. 2010 Apr;2(2):72-9
21814436
ChemMedChem. 2009 May;4(5):749-55
19343765
ACS Chem Biol. 2013 Aug 16;8(8):1775-84
23719508
ChemMedChem. 2007 Aug;2(8):1190-201
17589887
ChemMedChem. 2016 Feb 17;11(4):367-73
26812660
Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2081-5
7892228
Org Biomol Chem. 2006 Nov 7;4(21):3913-22
17047870
J Urol. 1990 Feb;143(2):330-2
2405189
Glycoconj J. 1998 Jun;15(6):605-13
9881767
PLoS One. 2016 Mar 31;11(3):e0152538
27031833
Cell Microbiol. 2012 Nov;14(11):1687-96
22882798
J Cell Sci. 2001 Nov;114(Pt 22):4095-103
11739641
PLoS Pathog. 2015 Jan 08;11(1):e1004599
25569799
Science. 2003 Jul 4;301(5629):105-7
12843396
Carbohydr Res. 2011 Sep 6;346(12):1503-10
21575933
Nat Rev Drug Discov. 2009 Aug;8(8):661-77
19629075
Carbohydr Res. 1986 Oct 15;154:145-63
3791292
FEMS Immunol Med Microbiol. 2003 Oct 15;38(3):181-91
14522453
Org Biomol Chem. 2016 Apr 28;14 (16):3913-25
27043998
Chem Rev. 2015 Jan 14;115(1):525-61
25495138
Mol Microbiol. 2002 May;44(4):903-15
12010488
J Med Chem. 2016 Apr 14;59(7):3163-82
26959338
Chemistry. 2013 Jun 10;19(24):7847-55
23595913
EBioMedicine. 2014 Oct 24;1(1):46-57
26125048
Dis Mon. 2003 Feb;49(2):53-70
12601337
Chembiochem. 2016 May 17;17(10):936-52
26946458
Infect Dis Clin North Am. 2014 Mar;28(1):1-13
24484571
Scand J Infect Dis. 2000;32(5):495-9
11055653
Expert Opin Ther Pat. 2016;26(2):175-97
26651364
J Med Chem. 2010 Jun 24;53(12):4779-92
20507142
Front Microbiol. 2010 Dec 08;1:134
21687759
J Mol Biol. 2011 Sep 23;412(3):520-35
21816158
PLoS Pathog. 2007 Jul;3(7):e100
17630833
Chemistry. 2004 Sep 6;10(17):4240-51
15352107
PLoS Pathog. 2010 Aug 12;6(8):e1001042
20811584